>

Press Releases

YEAR
Date Description View
12/20/17

Denali Therapeutics Announces Advancement And Expansion Of Its LRRK2 Inhibitor Clinical Program For Parkinson’s Disease

12/12/17

Denali Therapeutics Announces Closing Of Initial Public Offering, Including Full Exercise Of Underwriters’ Option To Purchase Additional Shares

12/07/17

Denali Therapeutics Announces Pricing Of Initial Public Offering

08/25/16

Denali Therapeutics Announces First Clinical Trial Application, Key Collaborations And $130M Series B

09/08/15

Denali Therapeutics Appoints Steve E. Krognes As Chief Financial Officer

07/22/15

Denali Therapeutics Appoints Carole Ho, M.D., As Chief Medical Officer And Head Of Development

05/14/15

Denali Therapeutics Launches With Initial Investment To Discover And Develop Treatments For Neurodegenerative Diseases

Investors & Media Relations